Pharming Group reports financial results for the first quarter of 2023
Financial updatesPharming Group N.V. presents its preliminary, unaudited financial report for the first quarter ended March 31, 2023.
Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023
Conference attendancePharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries will attend the H.C. Wainwright BioConnect Investor Conference 2023 on May 2, 2023 in New York and will take part in a fireside chat at 11:00 ET/17:00 CEST.
Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023
Conference attendancePharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries and Chief Financial Officer, Jeroen Wakkerman will attend the Van Lanschot Kempen Life Sciences Conference on April 25 and 26, 2023 in Amsterdam, the Netherlands.
Notice of First Quarter 2023 Results
Financial updatesPharming Group N.V. confirms it will announce first quarter 2023 financial results for the month ended March 31, 2023 on Thursday, May 11, 2023.
Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023
Conference attendancePharming Group N.V. announces that Pharming’s management will attend the 22nd Annual Needham Virtual Healthcare Conference April 17 - 20, 2023.
Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.
Operational updatesPharming Group N.V. announces the first commercial shipments of Joenja® (leniolisib) to patients in the United States.
Pharming Group convenes the Annual General Meeting of Shareholders 2023
Corporate updatesPharming Group N.V. announces that the Company’s 2023 Annual General Meeting of Shareholders (AGM) will be held on Wednesday, May 17, 2023, at 14:00 CEST.
Pharming Group announces the filing of its 2022 Annual Report and Form 20-F
Financial updatesPharming Group N.V. announces the filing of its Annual Report for the year ended December 31, 2022 (the “Period”).
Pharming to present at the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days
Conference attendancePharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries, and Chief Commercial Officer, Stephen Toor, will attend the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days, April 3 - 4, 2023 in New York.
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
Corporate updatesPharming Group N.V. announces that the US Food and Drug Administration (FDA) has approved Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Joenja®, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the US for APDS, a rare and progressive primary immunodeficiency.